Erythrodermic psoriasis treated with apremilast


https://doi.org/10.4081/dr.2016.6599
Vol. 8 No. 1 (2016)
Submitted: 13 May 2016
Accepted: 17 August 2016
Published: 19 September 2016
Erythroderma, Psoriasis, Erythrodermic psoriasis, Apremilast.
Abstract Views: 1823
PDF: 815
HTML: 594
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • John Arcilla Department of Medicine, Loma Linda University School of Medicine, VA Loma Linda Healthcare System, Loma Linda, CA, United States.
  • Daniel Joe Department of Medicine, Loma Linda University School of Medicine, VA Loma Linda Healthcare System, Loma Linda, CA, United States.
  • Johnathan Kim Department of Medicine, Loma Linda University School of Medicine, VA Loma Linda Healthcare System, Loma Linda, CA, United States.
  • Yohanan Kim Department of Medicine, Loma Linda University School of Medicine, VA Loma Linda Healthcare System, Loma Linda, CA, United States.
  • VuAnh N. Truong Department of Medicine, Loma Linda University School of Medicine, VA Loma Linda Healthcare System, Loma Linda, CA, United States.
  • Navin Jaipaul
    Navin.Jaipaul@va.gov
    Department of Medicine, Loma Linda University School of Medicine and Department of Medicine, VA Loma Linda Healthcare System, Loma Linda, CA, United States.
Erythroderma is a rare potentially deadly exfoliative dermatitis characterized by diffuse cutaneous erythema which may be associated with multi-organ dysfunction. Therefore, it is imperative to recognize and treat it promptly. Erythrodermic psoriasis is the most common form of erythroderma. Management of this condition is largely based on aggressive supportive care and the use of anti-inflammatory immunosuppressive and biologic agents. We describe a case of psoriatic erythroderma which was triggered by withdrawal from systemic steroids and successfully treated with apremilast and cyclosporine. Apremilast induced atrial fibrillation limited its continued use after the initial response period.

Navin Jaipaul, Department of Medicine, Loma Linda University School of Medicine and Department of Medicine, VA Loma Linda Healthcare System, Loma Linda, CA

Department of Medicine

Division of Nephrology

Associate Professor of Medicine

Supporting Agencies

None

Arcilla, J., Joe, D., Kim, J., Kim, Y., Truong, V. N., & Jaipaul, N. (2016). Erythrodermic psoriasis treated with apremilast. Dermatology Reports, 8(1). https://doi.org/10.4081/dr.2016.6599

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC